Home > Science > NNZ-2591Published Studies & Presentations > Phelan-McDermid Syndrome

Phelan-McDermid Syndrome

29-May-2025	Many Apparent False Negatives in Detection of Mutations in Gene Associated With Autism Spectrum Disorders

26-Mar-2025	Safety, Efficacy, and Exposure‑Response of NNZ‑2591, a Synthetic Analog of Cyclic Glycine‑Proline (cGP), an IGF‑1 Metabolite, for the Treatment of Phelan‑McDermid Syndrome in Children and Adolescents

26-Mar-2025	The Evolving Genetic Landscape of Phelan-McDermid Syndrome and Implications for Diagnostics

11-Nov-2024	Improving Outcome Measures for Trials in Phelan-McDermid Syndrome (PMS): Development of PMS-Specific Clinician and Caregiver Impression-of-Change Measures

11-Nov-2024	NNZ-2591, A Novel IGF-1–Related Treatment for Neurodevelopmental Disorders, Demonstrates Efficacy for Children and Adolescents With Phelan-McDermid Syndrome

14-Oct-2024	Safety, Efficacy, and Exposure‑Response of NNZ‑2591, a Synthetic Analog of Cyclic Glycine‑Proline (cGP), an IGF‑1 Metabolite, for the Treatment of Phelan-McDermid Syndrome in Children and Adolescents